ETFs positioned on Protagonist Therapeutics, Inc.

Name Weight AuM Varia. Jan 1. Investor
0.01% 7 M€ +13.60% -
0% 293,477 M€ +8.22% -
0% 31 M€ +3.37% -
Logo Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. The Company’s Interleukin-23 receptor (IL-23R) antagonist compound JNJ-2113 is an orally delivered investigational drug that is designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-943 is a wholly owned investigational orally delivered gut-restricted alpha 4 beta 7 (α4β7) specific integrin antagonist for inflammatory bowel disease (IBD).
Employees
128
More about the company
Trader
Investor
Global
Quality
ESG MSCI
BB
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
90.25USD
Average target price
92.83USD
Spread / Average Target
+2.86%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. PTGX Stock
  4. ETFs Protagonist Therapeutics, Inc.